Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Oltipraz in the Patients With Non-alcoholic Fatty Liver Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients over 18, under 75 years of age~* Patients with non-alcoholic fatty liver disease~Exclusion Criteria:~* Over 2 ratio of AST to ALT~* Type 1 diabetes mellitus (insulin-dependent diabetes mellitus)~* Disorder in liver function with an exception of non-alcoholic fatty liver (e.g. Virus infection, biliary atresia, autoimmune hepatitis and etc.)~* Patients who have been taken drugs induced fatty liver for over 3 month within 1 year of participation in this study; amiodarone, tamoxifen, methotrexate, tetracyclines, glucocorticoids, anabolic steroids, over usual dose of estrogen for hormone replacement therapy and valproate~* Patients who has been taken any medications that could affect the treatment for non-alcoholic steatohepatitis: insulin, insulin sensitizer(metformin, thiazolidinedione), high dose of vitamin E, high dose of UDCA, pentoxifylline, SAM-e, Betaine, types of Statin, types of fibrate and orlistat~* Patients who had a Bariatric surgery less than 6 month prior to the participation in the study~* Patients who are judged by investigator that participation of the study is difficult due to disease as follow; hepatic cirrhosis, Wilson's disease, malignant tumor, serious metabolic disease, severe renal disease, severe pulmonary disease, severe cardiovascular disease, severe nervous disease/psychiatric disorder, muscle disease and etc~* Any history of immune disorder which affect the changes in cytokine:~inflammatory bowel disease, autoimmune thrombocytopenic purpura, system lupus erythematosus, autoimmune hemolytic anemia, severe psoriasis, rheumatic arthritis and etc~* Patients who have received treatment that may affect liver function within 1 month prior to the participation in the study~* Patient who has been administered other investigational product within 1 month prior to the participation in the study~* Patient who is not allowed to get MRS test: pacemaker, shunt and etc~* Pregnant or nursing women~* Patient who considered ineligible for participation in the study as Investigator's judgment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Oltipraz (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).